caa a22 4500 475833252 CHVBK 20180406123846.0 cr unu---uuuuu 170329e20001201xx s 000 0 eng 10.1023/A:1007850527878 doi (NATIONALLICENCE)springer-10.1023/A:1007850527878 Adenosine A1 Agonist at Reperfusion Trial (AART): Results of a Three-Center, Blinded, Randomized, Controlled Experimental Infarct Study [Elektronische Daten] [G.F. Baxter, S.L. Hale, T. Miki, R.A. Kloner, M.V. Cohen, J.M. Downey, D.M. Yellon] Adenosine A1 receptor agonists given prior to myocardial ischemia limit ischemic injury in several species. However, the ability of adenosine receptor agonists to limit infarct size when given at reperfusion has proved controversial. We designed a three-center experimental study using a blinded, randomized treatment protocol to test the hypothesis that adenosine A1 receptor activation during early reperfusion can attenuate lethal reperfusion injury, thereby reducing infarct size. Sixty anesthetized rabbits (20 in each laboratory) underwent 30 minutes coronary artery occlusion followed by 120 minutes reperfusion. The selective adenosine A1 receptor agonist GR79236 (10.5 μg/kg, a dose shown to limit infarction in this model when given before ischemia) or vehicle were administered IV 10 minutes before reperfusion. Infarct size was assessed by tetrazolium staining and, after the randomization code was revealed, data from the three laboratories were pooled for statistical analysis. Infarct size was not modified by administration of GR79236. In the vehicle-treated group, the infarct-to-risk ratio was 28.9 ± 2.7% (n = 24) compared with 31.9 ± 2.6% (n = 26) in the GR79236-treated group (not significant). Risk zone volume was similar in the two groups (1.06 ± 0.05 cm3 vs 1.00 ± 0.05 cm3, respectively). A modest reduction in rate-pressure product was noted following the administration of GR79236, but this effect was transient. The same dose of GR79236 was found to limit infarct size when given prior to coronary artery occlusion. We conclude that A1 receptor activation does not modify lethal reperfusion injury in myocardium. Kluwer Academic Publishers, 2000 adenosine nationallicence A1 receptor agonist nationallicence GR79236 nationallicence infarct size nationallicence ischemia-reperfusion nationallicence reperfusion injury nationallicence Baxter G.F. The Hatter Institute, University College Hospital and Medical School, London, UK aut Hale S.L. Heart Institute, Hospital of the Good Samaritan, and University of Southern California, Los Angeles, CA, USA aut Miki T. Department of Physiology, Medical College, University of South Alabama, Mobile, AL, USA aut Kloner R.A. Heart Institute, Hospital of the Good Samaritan, and University of Southern California, Los Angeles, CA, USA aut Cohen M.V. Department of Physiology, Medical College, University of South Alabama, Mobile, AL, USA aut Downey J.M. Department of Physiology, Medical College, University of South Alabama, Mobile, AL, USA aut Yellon D.M. The Hatter Institute, University College Hospital and Medical School, London aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/6(2000-12-01), 607-614 0920-3206 14:6<607 2000 14 10557 https://doi.org/10.1023/A:1007850527878 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007850527878 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Baxter G.F. The Hatter Institute, University College Hospital and Medical School, London, UK aut NATIONALLICENCE 700 1- Hale S.L. Heart Institute, Hospital of the Good Samaritan, and University of Southern California, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Miki T. Department of Physiology, Medical College, University of South Alabama, Mobile, AL, USA aut NATIONALLICENCE 700 1- Kloner R.A. Heart Institute, Hospital of the Good Samaritan, and University of Southern California, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Cohen M.V. Department of Physiology, Medical College, University of South Alabama, Mobile, AL, USA aut NATIONALLICENCE 700 1- Downey J.M. Department of Physiology, Medical College, University of South Alabama, Mobile, AL, USA aut NATIONALLICENCE 700 1- Yellon D.M. The Hatter Institute, University College Hospital and Medical School, London aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/6(2000-12-01), 607-614 0920-3206 14:6<607 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer